Bernard Barlaam

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 155 citations · Full text

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake et al. · Clinical Cancer Research · 2010 · 118 citations

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-2-one)

Kurt G. Pike, Bernard Barlaam, Elaine Cadogan et al. · Journal of Medicinal Chemistry · 2018 · 111 citations · Full text

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

James S. Scott, Amber Balazs, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2020 · 109 citations · Full text

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson et al. · Molecular Cancer Therapeutics · 2014 · 99 citations · Full text